● any patents that are issued may not provide meaningful protection; ● we may not be able to develop additional proprietary technologies that are patentable; ● other companies may challenge patents licensed or issued to us; ● other companies may independently develop similar or alternative technologies, or duplicate our technologies; Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or Commission File No. 001-36203 (Name, Telephone, E-mail and/or F ...

Exhibit 99.1 PETACH TIKVA, Israel, March 30, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2022. PICLIDENOSON Pivotal Phase III Psoriasis Registration Plan for Piclidenoson Submitted to EMA – Can-Fite submitted a market registration plan to the European Medicines Agency (EMA) for Picliden ...

Exhibit 99.1 Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, November 25, 2022 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022. Corporate and Clinical Development Highlights Include: Complete Clearance of Cancer in a Patient Treated ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report________________________ For the transition period from__________ to _ ...

Exhibit 99.1 Can-Fite Reports 2021 Financial Results & Provides Clinical Update · Cash balance of $18.9 million as of December 31, 2021 · Signed out-licensing deal worth $42.7 million with Ewopharma · Phase III psoriasis topline data expected Q2 2022 · Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite's Phase II study · Phase IIb NASH study is currently enrolling patients · Pivotal Phase III advanced liver cancer study expected to commence enro ...

Exhibit 99.1 Can-Fite Reports 2021 Financial Results & Provides Clinical Update · Cash balance of $18.9 million as of December 31, 2021 · Signed out-licensing deal worth $42.7 million with Ewopharma · Phase III psoriasis topline data expected Q2 2022 · Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite's Phase II study · Phase IIb NASH study is currently enrolling patients · Pivotal Phase III advanced liver cancer study expected to commence enro ...

Exhibit 99.1 Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update PETACH TIKVA, Israel, November 26, 2021 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. Corporate and Clinical Development Highlights Include: Completed Patient Enrollment in Phase III Psorias ...

Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-36203 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT ...

Can-Fite BioPharma Ltd. (NYSE:CANF) Q3 2020 Earnings Conference Call November 30, 2020 9:15 AM ET Company Participants Paul Hoops - Investor Relations Pnina Fishman - Chief Executive Officer Motti Farbstein - Chief Financial Officer Conference Call Participants Peter Levine - Ameriprise Operator Greetings, and welcome to the Can-Fite BioPharma Third Quarter Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow t ...

Can-Fite Presentation August 2020 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement • This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". • Forward-lo ...